8-K: DiaMedica Reports Strong Q2 2025, Advances DM199

DiaMedica Therapeutics announced positive Phase 2 interim data for DM199 in preeclampsia, a $30 million private placement extending its cash runway, and progress in its ReMEDy2 stroke trial.

Summary

• Positive Phase 2 interim data for DM199 in preeclampsia showed statistically significant reductions in blood pressure and pulsatility index, with no placental transfer.
• A $30.1 million private placement increased proforma cash to $60 million, extending the cash runway into H2 2027.
• Enrollment for the ReMEDy2 Phase 2/3 trial for acute ischemic stroke is progressing, with interim data anticipated in Q2 2026.
• DiaMedica was included in the Russell 2000 and 3000 Indexes in June 2025.
• Julie Krop, MD, was appointed Chief Medical Officer in August 2025.
• Net loss for the three months ended June 30, 2025, was $7.7 million, up from $5.1 million in the same period of 2024.
• Research and Development (R&D) expenses increased to $5.8 million for Q2 2025 from $3.9 million for Q2 2024.
• General and Administrative (G&A) expenses increased to $2.2 million for Q2 2025 from $1.7 million for Q2 2024.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial results for a key pipeline candidate (DM199 in preeclampsia), a significant capital raise that extends the cash runway for over two years, and continued progress in another major trial (ReMEDy2). These operational and financial achievements significantly de-risk the company's near-term future, despite increased operating losses, which are typical for a clinical-stage biotech.

Positives

• Positive Phase 2 interim data for DM199 in preeclampsia, demonstrating highly statistically significant and clinically meaningful reductions in systolic and diastolic blood pressure.
• DM199 appeared safe and well-tolerated with no evidence of placental transfer in the preeclampsia trial.
• A highly statistically significant reduction in uterine artery pulsatility index suggested an improvement in uterine artery blood flow and placental perfusion.
• Successful $30.1 million private placement, increasing the proforma cash balance to $60 million.
• Extended cash runway into the second half of 2027, expected to fund planned clinical studies and corporate operations for over two years.
• Progressing enrollment in the ReMEDy2 Phase 2/3 trial for acute ischemic stroke.
• Inclusion in the Russell 2000 and 3000 Indexes in June 2025, enhancing visibility and liquidity.
• Appointment of Julie Krop, MD, as Chief Medical Officer, bringing over 20 years of strategic physician executive experience, including prior experience in preeclampsia drug development.

Negatives

• Net loss increased to $7.7 million for the three months ended June 30, 2025, compared to $5.1 million for the same period in 2024.
• Net loss increased to $15.4 million for the six months ended June 30, 2025, compared to $10.3 million for the same period in 2024.
• Research and Development (R&D) expenses increased to $5.8 million for Q2 2025 from $3.9 million for Q2 2024, primarily due to ReMEDy2 trial progress and global expansion.
• General and Administrative (G&A) expenses increased to $2.2 million for Q2 2025 from $1.7 million for Q2 2024, primarily due to additional non-cash share-based compensation and increased personnel costs.
• Cash, cash equivalents and short-term investments decreased to $30.0 million as of June 30, 2025, from $44.1 million as of December 31, 2024, prior to the private placement.
• Net cash used in operating activities for the six months ended June 30, 2025, was $14.7 million, an increase from $11.2 million for the same period in 2024.

Risks

• Existing preclinical and clinical data from DM199 as a treatment for preeclampsia may not be predictive of the results of ongoing or later clinical trials.
• Risks related to DiaMedica's plans to develop, obtain an IND for the clinical study of DM199 for preeclampsia and fetal growth restriction, and ultimately regulatory approval and commercialization.
• Uncertainty regarding the timing of ReMEDy2 trial enrollment, regulatory applications, and related filing and approval timelines.
• The possibility that enrollment in the ReMEDy2 trial will not continue to increase as anticipated.
• The possible occurrence of future adverse events associated with or unfavorable results from DiaMedica's current or future trials.
• DiaMedica's ability to conduct successful clinical testing of DM199 within its anticipated parameters, site activations, enrollment numbers, costs, and timeframes.
• The adaptive design of the ReMEDy2 trial and the possibility that targeted enrollment and other aspects of the trial could change depending upon certain factors, including additional input from the FDA and the blinded interim analysis.
• Risks related to the perceived benefits of DM199 over existing treatment options.
• Potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs, and worldwide global supply chain shortages on DiaMedica's business and clinical trials.
• DiaMedica's reliance on collaboration with third parties to conduct clinical trials.
• DiaMedica's ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals.

Future Outlook

The company anticipates submitting an Investigational New Drug (IND) application for DM199 in the U.S. for preeclampsia and fetal growth restriction, followed by a Phase 2b study if accepted. Enrollment for the ReMEDy2 Phase 2/3 trial is expected to complete its interim analysis on the first 200 patients in Q2 2026. The recent capital raise is expected to fund operations into the second half of 2027.

Management Comments

• "With the recent positive interim results from Part 1a of our Phase 2 study evaluating DM199 in preeclampsia followed by a $30M capital raise, we're eager to continue advancement of this promising candidate to address ischemic diseases in the second half of this year." Rick Pauls, President and CEO.
• "Preeclampsia and fetal growth restriction are areas with high unmet medical need due to the lack of approved treatment options, and we believe DM199 has the potential to provide a disease-modifying solution for patients suffering from these ischemic conditions." Rick Pauls, President and CEO.
• "We look forward to submitting an investigational new drug application for DM199 in the U.S. to further evaluate its potential in preeclampsia and fetal growth restriction, while initiating subsequent parts of the ongoing investigator-sponsored Phase 2 trial in these indications." Rick Pauls, President and CEO.

Industry Context

The biopharmaceutical industry is highly competitive and research-intensive, with significant unmet medical needs in areas like preeclampsia, fetal growth restriction, and acute ischemic stroke. DiaMedica's focus on DM199, a recombinant KLK1 protein, positions it in a niche with an established therapeutic modality in Asia, but novel for Western markets. The lack of approved treatments for preeclampsia and fetal growth restriction highlights a substantial market opportunity for a disease-modifying solution. Successful clinical progress and securing funding are critical for clinical-stage companies in this sector to advance their pipelines and address these high-need indications.

Comparison to Industry Standards

• The filing highlights the "high unmet medical need" for preeclampsia and fetal growth restriction due to a "lack of approved treatment options," indicating that DM199, if successful, could be a first-in-class or best-in-class solution in these areas.
• DM199 is noted as the first pharmaceutically active recombinant form of the KLK1 protein, which is an established therapeutic modality in Asia for acute ischemic stroke and other vascular diseases, suggesting a validated mechanism of action, though its application in Western markets for these specific indications is novel.
• While specific comparable companies or projects are not detailed in the filing, the positive Phase 2 interim data showing statistically significant reductions in blood pressure and pulsatility index, along with no placental transfer, are strong indicators of potential efficacy and safety, which are critical benchmarks for drug candidates in maternal-fetal medicine.
• The successful $30.1 million private placement and extended cash runway into H2 2027 are significant achievements for a clinical-stage biopharmaceutical company, providing financial stability often sought by investors in this capital-intensive industry.

Management Changes

Legal Proceedings

• A reduction in legal fees incurred in connection with a lawsuit against PRA Netherlands was noted, implying ongoing or recently concluded legal matters.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, extended cash runway, and inclusion in Russell indexes, potentially increasing share price and liquidity. Increased net loss and expenses are a negative, but offset by the positive developments.
• Patients (Preeclampsia, Fetal Growth Restriction, AIS): Potential for a novel, disease-modifying treatment (DM199) for conditions with high unmet medical needs.
• Employees: Continued employment and potential growth opportunities due to pipeline advancement and extended funding. Increased personnel costs noted.
• Creditors: Improved financial stability due to extended cash runway.
• Regulatory Authorities: Upcoming IND submission for DM199 in the U.S. will involve engagement with the FDA.

Next Steps

• Submission of an Investigational New Drug (IND) application for DM199 in the U.S. for preeclampsia and fetal growth restriction.
• Initiation of subsequent parts of the ongoing investigator-sponsored Phase 2 trial in preeclampsia and fetal growth restriction.
• If IND accepted, initiation of a Phase 2b study to further evaluate DM199 in preeclampsia and fetal growth restriction.
• Completion of interim analysis on the first 200 patients in the ReMEDy2 Phase 2/3 trial, anticipated in Q2 2026.
• Conference call and webcast on August 13, 2025, to discuss results.

Key Dates

Recommendation

The filing indicates significant positive momentum for DiaMedica. The highly positive Phase 2 interim data for DM199 in preeclampsia, showing statistically significant efficacy and a clean safety profile, is a major de-risking event for a clinical-stage biopharmaceutical company. This, coupled with a successful $30.1 million private placement that extends the cash runway into H2 2027, provides crucial financial stability to advance the pipeline. The continued progress in the ReMEDy2 stroke trial and inclusion in the Russell indexes further enhance the company's profile and potential liquidity. While net losses increased, this is expected for a company in active clinical development. The combination of strong clinical validation, robust funding, and strategic corporate developments makes this a compelling investment opportunity with significant upside potential, warranting a "strong buy" recommendation for investors comfortable with biotech risk.

Keywords

Biopharmaceutical, Preeclampsia, Fetal Growth Restriction, Acute Ischemic Stroke, DM199, Clinical Trial, Phase 2, Phase 3, ReMEDy2, KLK1, Drug Development, Nasdaq, Russell 2000, Russell 3000, Biotech, Therapeutics